Abstract
Importance While much of the attention on the COVID-19 pandemic was directed at the daily counts of cases and those with serious disease overwhelming health services, increasingly, reports have appeared of people who experience debilitating symptoms after the initial infection. This is popularly known as long COVID.
Objective To estimate by country and territory of the number of patients affected by long COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery
Design We jointly analyzed ten ongoing cohort studies in ten countries for the occurrence of three major symptom clusters of long COVID among representative COVID cases. The defining symptoms of the three clusters (fatigue, cognitive problems, and shortness of breath) are explicitly mentioned in the WHO clinical case definition. For incidence of long COVID, we adopted the minimum duration after infection of three months from the WHO case definition. We pooled data from the contributing studies, two large medical record databases in the United States, and findings from 44 published studies using a Bayesian meta-regression tool. We separately estimated occurrence and pattern of recovery in patients with milder acute infections and those hospitalized. We estimated the incidence and prevalence of long COVID globally and by country in 2020 and 2021 as well as the severity-weighted prevalence using disability weights from the Global Burden of Disease study.
Results Analyses are based on detailed information for 1906 community infections and 10526 hospitalized patients from the ten collaborating cohorts, three of which included children. We added published data on 37262 community infections and 9540 hospitalized patients as well as ICD-coded medical record data concerning 1.3 million infections. Globally, in 2020 and 2021, 144.7 million (95% uncertainty interval [UI] 54.8–312.9) people suffered from any of the three symptom clusters of long COVID. This corresponds to 3.69% (1.38–7.96) of all infections. The fatigue, respiratory, and cognitive clusters occurred in 51.0% (16.9–92.4), 60.4% (18.9–89.1), and 35.4% (9.4–75.1) of long COVID cases, respectively. Those with milder acute COVID-19 cases had a quicker estimated recovery (median duration 3.99 months [IQR 3.84–4.20]) than those admitted for the acute infection (median duration 8.84 months [IQR 8.10–9.78]). At twelve months, 15.1% (10.3–21.1) continued to experience long COVID symptoms.
Conclusions and relevance The occurrence of debilitating ongoing symptoms of COVID-19 is common. Knowing how many people are affected, and for how long, is important to plan for rehabilitative services and support to return to social activities, places of learning, and the workplace when symptoms start to wane.
Question What are the extent and nature of the most common long COVID symptoms by country in 2020 and 2021?
Findings Globally, 144.7 million people experienced one or more of three symptom clusters (fatigue; cognitive problems; and ongoing respiratory problems) of long COVID three months after infection, in 2020 and 2021. Most cases arose from milder infections. At 12 months after infection, 15.1% of these cases had not yet recovered.
Meaning The substantial number of people with long COVID are in need of rehabilitative care and support to transition back into the workplace or education when symptoms start to wane.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: C Adolph reports support for the present manuscript from the Benificus Foundation. P Bobkova, A Gamirova, A Shikhaleva, and A Svistunov report grants from the British Embassy in Moscow StopCOVID Cohort: Clinical Characterisation of Russian Patients 2020-2021 paid to Sechenov University, outside the submitted work. X Dai reports support for the present manuscript from Bloomberg Philanthropies and the Bill & Melinda Gates Foundation, paid to the Institute for Health Metrics and Evaluation. A Flaxman report stock options from Agathos, Ltd., and provides technical advising on simulation modeling for Janssen, SwissRe, Merck for Mothers, and Sanofi, outside the submitted work. R Frithiof reports support for the present manuscript from The Swedish Research Council and the Swedish Kidney Foundation, paid to Uppsala University. N Fullman reports funding from WHO for consultant work in 2019 and funding from Gates Ventures since 2020, outside the submitted work. A Gamirova reports grants and contracts from the British Embassy in Moscow (PI): StopCOVID Cohort: Clinical Characterisation of Russian Patients 2020-2021, paid to Sechenov University. J Haagsma reports grants from the EuroQol Foundation, outside the submitted work. M Heijenbrok-Kal and R van den Berg-Emons report support for the present manuscript from ZonMW Program COVID-19, Laurens, and Rijndam Rehabilitation, paid to Erasmus MC. M Hultstrom reports support for the present manuscript from Knut and Alice Wallenburg Foundation, Swedish Heart-Lung Foundation, and Swedish Society of Medicine, paid to Uppsala University. M Lipcsey reports grants or contracts from Hjart-lungfonden Sweden and is a member of the PROFLO RCT and COVID-19_HBO data safety monitoring boards, outside the submitted work. D Munblit reports report grants from the British Embassy in Moscow StopCOVID Cohort: Clinical Characterisation of Russian Patients 2020-2021, Russian Foundation for Basic Research Grant Cell therapy and prevention of ARDS during COVID infection: from basic science to clinical practice 2020-2022, all paid to Sechenov University, and was awarded a UK Research and Innovation/National Institute for Health Research grant, payment for lectures given to Merch Sharp & Dohme and Bayer, and reports unpaid leadership positions as co-chair of International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric Long COVID Working Group and co-lead of the PC-COS project aiming to define the Core Outcome Set for Long-COVID in collaborator from WHO, and is a member of the ISARIC working group on long-term COVID follow-up in adults, all outside the submitted work. S Nomura reports support for the present manuscript from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. M S Petersen reports support for the present manuscript from Cooperation p/f Krunborg and Borgartun, grants or contracts from the Velux Foundation, special COVID-10 funding from the Faroese Research Council, the Faroese Parkinson association, and the Faroese Health Insurance Fund, participation on the Board of the Faroese National Data Protection Authority, and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Wantai Total Ab ELISA, outside the submitted work. M Puhan reports support from the University of Zurich Foundation and the Department of Health, Canton of Zurich. A Shikhaleva reports grants and contracts from the British Embassy in Moscow (PI): StopCOVID Cohort: Clinical Characterisation of Russian Patients 2020-2021, paid to Sechenov University. E Spiridonova reports grants and contracts from the British Embassy in Moscow (PI): StopCOVID Cohort: Clinical Characterisation of Russian Patients 2020-2021, paid to Sechenov University. A Svistunov reports a grant from the Russian Foundation for Basic Research Grant Cell therapy and prevention of ARDS during COVID infection: from basic science to clinical practice 2020-2022, paid to Sechenov University. R van den Berg-Emons reports support for the present manuscript from ZonMW Program COVID-19, grant for CO-FLOW study project number 10430022010026, Laurens funding for the CO-FLOW study, and from Rijndam Rehabilitation for the CO-FLOW study, all paid to Erasmus MC.
Funding Statement
The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation. The COFLOW study is funded by the COVID-19 Program Care and Prevention of The Netherlands Organization for Health Research and Development (ZonMw, grant number 10430022010026), and Rijndam Rehabilitation and Laurens (both in Rotterdam, The Netherlands). A Ferrari and D F Santomauro D F Santomauro are affiliated with the Queensland Centre for Mental Health Research, which receives core funding from the Department of Health, Queensland Government. C Adolph gratefully acknowledges support from the Benificus Foundation. C Wiysonge is supported by the South African Medical Research Council. H Xu received support from the National Institute on Aging (R21AG061142; R03AG064303) and the National Institute on Minority Health and Health Disparities (U54MD012530). R C Reiner and A Aravkin were partially supported by NSF Rapid grant #2031096. N Sarrafzadegan, S Haghjooy Javanmard, and N Mohammadifard report support for the Isfahan cohort study from grant number 199093 from the IUMS, grant number RPPH 20 76 from the WHO/EMR, grant number 996353 from the National Institute of Health Researches of Iran, and grant number 99008516 from the Iran National Science Foundation. M S Petersen reports support for the present manuscript from Cooperation p/f Krunborg and Borgartun, grants or contracts from the Velux Foundation, special COVID-10 funding from the Faroese Research Council, the Faroese Parkinson association, and the Faroese Health Insurance Fund. For this work, Lorenzo Monasta received supported from the Ministry of Health, Rome, Italy, in collaboration with the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Washington gave ethical approval for this work (study number 9060).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
